Additionally, to reduce immune escape and increase the target specificity concomitantly, some studies developed a novel tandem CAR T cells with PD1 and an anti-MUC1 scFv, which showed more potent antitumor activity in vivo and significantly prolonged the survival time of tumor bearing mice (88), suggesting that combination checkpoint blockade-CAR-T cell therapy is likely a new immunotherapy option in solid tumor. The gene discussed is PDCD1; the disease is neoplasm.